SASherzod Abdullaev

Sherzod Abdullaev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sherzod Abdullaev has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness of Ferric Carboxymaltosate on Renal Function in Patients with Chronic Kidney Disease

    by Sherzod Abdullaev

    Background: Iron deficiency anemia is common in patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes. Ferric carboxymaltose (FCM) is an effective and well-tolerated treatment for iron deficiency anemia in CKD. However, its potential effects on renal function remain insufficiently understood. This study aimed to evaluate changes in renal function following FCM administration in patients with CKD stages 3–4 and to assess whether these changes were associated with the administered dose. Methods: This prospective study included patients with CKD stages 3–4, anemia, and iron deficiency (serum ferritin <100 μg/L or <200 μg/L with transferrin saturation <20%) who received intravenous FCM (Fercari) and were followed for 24 weeks. Patients were stratified according to the administered dose: 500 mg or 1000 mg. Clinical and laboratory parameters were assessed at baseline and after 24 weeks. Renal function was evaluated using estimated glomerular filtration rate (eGFR) calculated by the CKD-EPI equation. Results: A total of 56 patients were included; mean age was 64.3 ± 6.7 years, and 25 (44.6%) were men. Diabetes mellitus, chronic heart failure, and arterial hypertension were present in 34 (60.7%), 31 (55.3%), and 45 (80.3%) patients, respectively. CKD stage 3 was present in 20 (35.7%) patients and stage 4 in 36 (64.3%). Thirty-two patients (57.1%) received 1000 mg FCM. Baseline mean hemoglobin was 98.3 ± 4.23 g/L and mean eGFR was 39.18 ± 15.14 mL/min/1.73 m². After 24 weeks, hemoglobin increased by 12.3 ± 1.51 g/L in the overall cohort (P=0.001), with increases of 15.6 ± 3.71 g/L in the 1000 mg group and 8.8 ± 1.5 g/L in the 500 mg group (both P=0.001). Mean eGFR increased by 5.86 ± 2.13 mL/min/1.73 m² in the overall cohort (P=0.042). In the 1000 mg group, eGFR increased by 6.64 ± 2.55 mL/min/1.73 m² (P=0.049), whereas no statistically significant change was observed in the 500 mg group. Conclusions: FCM effectively improved hemoglobin levels in patients with CKD stages 3–4 and iron deficiency anemia. Treatment with 1000 mg FCM was associated with a modest improvement in eGFR over 24 weeks, whereas no significant change was observed with 500 mg. These findings suggest a possible dose-related association between FCM treatment and renal function; however, controlled randomized studies are required to determine whether this represents a true nephroprotective effect.

  • Open Access

    Exome-wide association study of bleeding events in patients receiving direct oral anticoagulants

    by Dmitry A Sychev, Anastasiia A Buianova, Sherzod P Abdullaev, Karin B Mirzaev, Vera A Belova, Anna O Shmitko, Valery V Cheranev, Oleg N Suchalko, Lyudmila V Fedina, Svetlana V Batyukina, et al.

    Background: Direct oral anticoagulants (DOACs) are first-line medications for stroke prevention in non-valvular atrial fibrillation (AF). However, variability in drug response poses risks of hemorrhagic or thromboembolic events. Objectives: Although genetic influences on DOACs safety are increasingly recognized, robust evidence directly linking specific polymorphisms to bleeding risk remains limited. Design: Multi-center observational case–control study including exome-wide association analysis of 196 non-valvular AF patients treated with rivaroxaban or apixaban, comprising 97 with bleeding complications and 99 without. Methods: DOAC plasma concentrations, urinary 6-β-hydroxycortisol and cortisol levels were measured for CYP3A4 phenotyping. Sequencing was performed on the DNBSEQ G-400 platform. Single-nucleotide variant (SNV) associations with bleeding risk were assessed using logistic regression with additive, dominant, and recessive genetic models. Polygenic risk scores (PRSs) were calculated to evaluate cumulative genetic effects. Results: No SNVs reached Bonferroni-corrected significance under any model. PRSs showed weak predictive ability for bleeding with apixaban. For rivaroxaban, regression indicated that ln C ss min /D + 1 index increased with PRS, age, and 6-β-hydroxycortisol/cortisol ratio, but decreased with higher 6-β-hydroxycortisol and coronary heart disease presence. No statistically significant differences were found for the PharmGKB Level 3 variants rs1045642 (rivaroxaban) and rs2231142 (apixaban). Trends toward statistical significance were observed for the rs2472304-G variant in rivaroxaban users, rs6977165-C in apixaban users, and for the CYP3A4*1/*36 diplotype. Conclusion: Residual equilibrium concentration of DOACs, including dose-adjusted, did not independently predict bleeding risk in non-valvular AF patients. Variants rs2472304 and rs6977165 may warrant further investigation as potential contributors to bleeding risk.


  • Open Access

    Awareness of chronic kidney disease and its risk factors in the former Soviet Union countries

    by Alimzhan Muxunov, Nikolay Bulanov, Sultan Makhmetov, Olimkhon Sharapov, Sherzod Abdullaev, Olena Loboda, Dinara Aiypova, Elgun Haziyev, Ismoil Rashidov, Irma Tchokhonelidze, et al.

    Purpose: Assessment of public knowledge of chronic kidney disease (CKD) is an essential step in development of CKD prevention and screening programs. Our aim was to estimate the level of public CKD knowledge and its predictors in the former Soviet Union countries using a validated questionnaire. Materials and methods: This cross-sectional survey was conducted in 10 countries using an adapted validated online questionnaire. Descriptive statistics were used to describe participants’ characteristics and assess public CKD knowledge level. A multiple linear regression analysis was performed to identify predictors of CKD knowledge. Results: 2,715 participants satisfied the inclusion criteria. Respondents having higher level of education, living in countries belonging to the lower middle-income countries, having a personal history of diabetes and hypertension, and having a family history of kidney disease showed significantly better CKD knowledge. Conclusions: The level of CKD knowledge among the population of post-Soviet states was found to be low, although some personal characteristics were associated with better CKD knowledge.


  • Open Access

    Epidemiological, clinical and morphological aspects of kidney damage in COVID-19

    by Batir Daminov, Sherzod Abdullaev, Olimkhon Sharapov, Ranokhon Igamberdieva

    The mini-review presents modern data on the epidemiology, clinical and morphological aspects of kidney damage in COVID-19. Potential mechanisms of kidney involvement in the clinical picture of the disease may include cytokine damage, cross-organ damage, and systemic effects that determine the treatment strategy. These mechanisms are closely interrelated and are especially important for individuals undergoing extracorporeal therapy and kidney transplants. Autopsy data provide evidence of SARS-CoV-2 virus invasion into kidney tissue with damage to tubular epithelial cells and podocytes, and erythrocyte aggregation in persons with severe COVID-19. By including people with chronic kidney disease in planned COVID-19 research protocols, an evidence base for effective and safe treatments can be generated.


  • Cartographic atlas of frequency variation for 45 pharmacogenetic markers in populations of Russia and its neighbor states

    by Ev Balanovska, Vs Petrushenko, Sm Koshel, Ea Pocheshkhova, Dk Chernevskiy, Kb Mirzaev, ShP Abdullaev, Op Balanovsky

    The lack of information about the frequency of pharmacogenetic markers in Russia impedes the adoption of personalized treatment algorithms originally developed for West European populations. The aim of this paper was to study the distribution of some clinically significant pharmacogenetic markers across Russia. A total of 45 pharmacogenetic markers were selected from a few population genetic datasets, including ADME, drug target and hemostasis-controlling genes. The total number of donors genotyped for these markers was 2,197. The frequencies of these markers were determined for 50 different populations, comprised of 137 ethnic and subethnic groups. A comprehensive pharmacogenetic atlas was created, i.e. a systematic collection of gene geographic maps of frequency variation for 45 pharmacogenetic DNA markers in Russia and its neighbor states. The maps revealed 3 patterns of geographic variation. Clinal variation (a gradient change in frequency along the East-West axis) is observed in the pharmacogenetic markers that follow the main pattern of variation for North Eurasia (13% of the maps). Uniform distribution singles out a group of markers that occur at average frequency in most Russian regions (27% of the maps). Focal variation is observed in the markers that are specific to a certain group of populations and are absent in other regions (60% of the maps). The atlas reveals that the average frequency of the marker and its frequency in individual populations do not indicate the type of its distribution in Russia: a gene geographic map is needed to uncover the pattern of its variation.


  • QUERCETIN INCREASES NITRIC OXIDE-DEPENDENT DILATION IN RAT THORACIC AORTA

    by S. Abdullaev, L. Kozaeva, O. Medvedev, E. Ruuge

    Endothelial dysfunction plays an important role in development and progression of arterial hypertension. In recent years there was reported that polyphenolic compounds improve the function of endothelium, however, their molecular mechanisms on endothelial cells remain unclarified. Purpose of study was to determine whether polyphenols (quercetin, caffeic acid or resveratrol) are able to improve NO-dependent vasodilation in rat aortic rings. Male Wistar rats were anaesthetized by chloralhydrate over dose and decapitated. Descending thoracic aorta was carefully excised and cut into ring segments 3 mm in length and then transferred into organ baths containing Krebs solution bubbled with mixture of 95% O2 and 5% CO2. Rings were precontracted with 0.3 uM Phenylephine and increasing concentrations of acetylcholine (Ach, 0.001 uM - 30 uM) were cumulatively added to organ bath. At the beginning of each experiment, all rings were pretreated with diclofenac for 30 minutes to prevent the generation of vasoactive prostanoid metabolites. Quercetin, caffeic acid or resveratrol (10 uM) was added to organ baths for 20 minutes before investigation of relaxant responses to ACh. Some rings were incubated in the DMSO (solvent, control). ACh elicited a concentration-dependent relaxation of rat aortic rings. After exposure to quercetin the relaxant responses to all concentrations of ACh were markedly potentiated. There was no significant relaxant response to ACh in caffeic acid and resveratrol groups. Maximum relaxation (E max, %) was increased from 54.6 ± 3.3 in control group to 67.3 ± 3.8 in quercetin group, and 63.4 ± 4.8 and 62.4 ± 5.1 in caffeic acid and resveratrol group, respectively (P < 0.05). Negative logarithm of EC50 (pD2) value in control study was 5.2 ± 0.28. After pretreatment with quercetin, caffeic acid and resveratrol pD2 values were 6.1 ± 0.16, 5.6 ± 0,18 and 5.4 ± 0.32, respectively (P < 0.005 vs. control). Our results demonstrate that quercetin improves endothelial dysfunction due to increased NO-dependent vasodilation. This mechanism could be associated with decrease in the ROS level and related decrease in inactivation of NO, or with activation of eNOS and related increase in NO synthesis in the endothelium. Study was supported by grant from Russian Foundation for Basic Research 15-04-05-211.


  • Left Ventricular Structure during Antihypertensive Treatment in Patients with Chronic Kidney Disease

    by Batir T. Daminov, Tashkent Pediatric Medical Institute, Sherzod Abdullaev, Uzbekistan Tashkent Medical Academy; Tashkent